Acquisition - HealthQuill

Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to a statement.

Johnson & Johnson to buy Proteologix Inc., for $850 million in cash

HQ Team May 17, 2024: Johnson & Johnson will acquire Proteologix, Inc., a privately-held biotechnology company, for $850 million in cash, according to.

by HealthQuill
May 17, 2024
0 Comments

Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex's planned acquisition of Femoston and Duphaston stating it may reduce competition and choice for hormone replacement therapy (HRT) treatments in the country.

Drugs Health Pharma

Britain’s CMA raises concern over Theramex’s Femoston buy

HQ Team April 4, 2024: Britain’s Competition and Markets Authority (CMA) expressed concerns over Theramex’s planned acquisition of Femoston and Duphaston stating it.

by HealthQuill
April 4, 2024
0 Comments

Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises in heart diseases, for up to 1.03 billion euros ($1.1 billion).

Drugs Health Pharma

Novo to buy Cardior for $1.1b to expand cardiovascular segment

HQ Team March 25, 2024: Novo Nordisk, one of the world’s most valuable companies, will acquire Germany-based Cardior Pharmaceuticals, a firm that specialises.

by HealthQuill
March 25, 2024
0 Comments

Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.

Drugs Health Pharma

AstraZeneca to acquire Fusion Pharmaceuticals for $2 billion in cash

HQ Team March 20, 2024: Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the.

by HealthQuill
March 20, 2024
0 Comments

Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss firm access to a key drug for treating blood cancer.

Drugs Health Pharma

Novartis to buy MorphoSys for $2.9 billion to expand cancer portfolio

HQ Team February 6, 2024: Novartis AG is set to buy a German-based biotechnology company, MorphoSys AG, for $2.9 billion, giving the Swiss.

by HealthQuill
February 6, 2024
0 Comments

Eli Lilly, a US company that forecasts revenue of up to $33.9 billion, plans to build a $2.5 billion plant in Germany to make devices for treating diabetes and obesity.

Drugs Health Pharma

Novo Nordisk buys 3 Catalent sites for $11bn to meet rising demand for Wegovy

HQ Team February 5, 2024: Novo Nordisk will acquire three manufacturing sites in an $11bn deal to expand its production of weightless drugs.

by HealthQuill
February 5, 2024
0 Comments

British drugmaker GSK Plc., will pay $1.4 billion to acquire Anglo-American biopharmaceutical company Aiolos Bio Inc., which makes medicines to treat asthma.

Drugs Health Pharma

GSK Plc., to buy asthma drugmaker Aiolos Bio for $1.4 billion

HQ Team January 9, 2023: British drugmaker GSK Plc., will pay $1.4 billion to acquire Anglo-American biopharmaceutical company Aiolos Bio Inc., which makes.

by HealthQuill
January 9, 2024
0 Comments

Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash.

Drugs Health Pharma

J&J to purchase Ambrx Biopharma for $2 billion in all-cash deal

HQ Team January 8, 2023: Johnson & Johnson will buy Ambrx Biopharma, Inc., a company developing targeted chemotherapy treatments, for $2 billion in cash..

by HealthQuill
January 8, 2024
0 Comments

Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio, the companies announced.

Drugs Health Pharma

Bristol Myers to acquire Karuna Therapeutics for $14 billion

HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.